Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Adam Fine
AddedMar 31, 2024
UpdatedMay 31, 2026
Adam Fine

Adam Fine

CEO, Windham Venture Partners

CrunchbaseLinkedIn

Adam Fine's Career

Windham Venture Partners
Windham Venture Partners

New York City, NY, US

CEO· C-Suite · Management
CuraSeal
CuraSeal

Santa Clara, CA, US

Board Member· Board
andros
andros

New York City, NY, US

Board Member· Board
Neuspera Medical
Neuspera Medical

San Jose, CA, US

Board Member· Board
Glysens
Glysens

San Diego, CA, US

Board Member· Board
MC10
MC10

Cambridge, MA, US

Board Member· Board
Coravin
Coravin

Bedford, MA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Adam Fine's Career

Windham Venture Partners
Windham Venture Partners
Investment FirmInvestment Firm152006New York City, NY, US
CEO· C-Suite · Management

Leadership at Windham Venture Partners

Kush ModyKush ModyBoard Member
Joe ProtoJoe ProtoCo-Founder
Roger S. FineRoger S. FineBoard Member
Riccardo BragliaRiccardo BragliaBoard Member
CuraSeal
CuraSeal
Pre-Seed$4M72007Santa Clara, CA, US
Board Member· Board

Leadership at CuraSeal

Harold CarrisonHarold CarrisonCo-Founder
Kenton FongKenton FongCo-Founder
Darpan MunjalDarpan MunjalCo-Founder
Akshay MavaniAkshay MavaniCo-Founder

Similar to CuraSeal

CuraSen TherapeuticsCuraSen TherapeuticsSan Carlos, CA, USDrugsest. 2016CuraSen TherapeuticsSan Carlos, CA, US · est. 2016

CuraSen: A biotech firm innovating drugs for CNS and neurodegenerative diseases enhancement.

Series A · $95.9M38
HistogenHistogenSan Diego, CA, USMedical Technologiesest. 2007HistogenSan Diego, CA, US · est. 2007

San Diego-based Histogen Inc. innovates patented medical technologies for aesthetic and therapeutic tissue replacement.

Public · $87.5M7
Caeregen TherapeuticsCaeregen TherapeuticsChapel Hill, NC, USRegenerative Medicine, Therapeuticsest. 2010Caeregen TherapeuticsChapel Hill, NC, US · est. 2010

Caeregen Therapeutics: Innovating regenerative medicine to repair, restore, and protect damaged tissues.

Pre-Seed · $1.4M5
CardiovateCardiovateSan Antonio, TX, USMedical Devicesest. 2012CardiovateSan Antonio, TX, US · est. 2012

Cardiovate: A med-tech company focusing on tissue regeneration and repair in healthcare.

Seed · $1.1M5
andros
andros
Series B$39.9M1602013New York City, NY, US
Board Member· Board

Leadership at andros

Mike SimmonsMike SimmonsCo-Founder
Steve HirschfeldSteve HirschfeldBoard Member
Garry ChoyGarry ChoyCo-Founder
Jeff L FritzJeff L FritzCEO
Sam MeyerSam MeyerCo-Founder

Similar to andros

CertifyOSCertifyOSNew York City, NY, USData Platformest. 2021CertifyOSNew York City, NY, US · est. 2021

CertifyOS: An API-first platform for real-time network management, verification, and credentialing.

Series A · $19.1M97
ProviderTrustProviderTrustNashville, TN, USCompliance Softwareest. 2010ProviderTrustNashville, TN, US · est. 2010

ProviderTrust: Streamlining healthcare credential management through innovative software solutions.

Private Equity · $1.8M134
Anchor HealthAnchor HealthSan Francisco, CA, USHealthcare, Softwareest. 1997Anchor HealthSan Francisco, CA, US · est. 1997

Anchor Health: Providing software, hardware, and operating solutions for distributed healthcare networks.

Seed · $120k5
ProtenusProtenusBaltimore, MD, USHealthcare Softwareest. 2014ProtenusBaltimore, MD, US · est. 2014

Protenus, an award-winning healthcare software provider, uses AI to deliver risk-reduction solutions, ensuring patient safety.

Series D · $57.2M123
Neuspera Medical
Neuspera Medical
Series C$111.9M312013San Jose, CA, US
Board Member· Board

Leadership at Neuspera Medical

Milton M. MorrisMilton M. MorrisBoard Member
Mudit K JainMudit K JainBoard Member
Steffen HovardSteffen HovardCEO
Alexander YehAlexander YehFounder
Lori HuLori HuBoard Member
Glysens
Glysens
Series D$34M751998San Diego, CA, US
Board Member· Board

Leadership at Glysens

David GoughDavid GoughCo-Founder
Joseph LucisanoJoseph LucisanoCo-Founder
William H. MarkleWilliam H. MarkleCEO
Dr Robert L EnglerDr Robert L EnglerBoard Member
Dr Orville G KoltermanDr Orville G KoltermanBoard Member

Similar to Glysens

Beta BionicsBeta BionicsIrvine, CA, USMedical Devicesest. 2015Beta BionicsIrvine, CA, US · est. 2015

Biotech firm, Beta Bionics, innovates bionic pancreas systems for improved diabetes care in the US.

Series D · $293.5M160
DiabetesManager.ComDiabetesManager.ComColorado Springs, CO, USDiabetes Management, Home Careest. 2000DiabetesManager.ComColorado Springs, CO, US · est. 2000

DiabetesManager.com provides affordable, intensive diabetes management services and home care support to patients globally.

Series B · $3M50
Ingram MedicalIngram MedicalOrem, UT, USDiabetes Suppliesest. 2011Ingram MedicalOrem, UT, US · est. 2011

Ingram Medical: A US-based provider of diabetes testing supplies.

Series B · $30M75
GlumetricsGlumetricsIrvine, CA, USGlucose Monitors, Medical Devicesest. 2005GlumetricsIrvine, CA, US · est. 2005

GluMetrics Inc.: A US-based medical device company specializing in innovative glucose monitoring solutions.

Series A · $68.2M30
MC10
MC10
Series A$97.4M382008Cambridge, MA, US
Board Member· Board

Leadership at MC10

Roozbeh GhaffariRoozbeh GhaffariCo-Founder
Gilman CallsenGilman CallsenCo-Founder
Paul H. KlingensteinPaul H. KlingensteinBoard Member
Jiong MaJiong MaBoard Member
Carmichael RobertsCarmichael RobertsBoard Member
George WhitesidesGeorge WhitesidesCo-Founder
Coravin
Coravin
Series B$64.3M1262011Bedford, MA, US
Board Member· Board

Leadership at Coravin

Christopher LaddChristopher LaddBoard Member
Jérôme ChevalierJérôme ChevalierBoard Member
Josh MakowerJosh MakowerBoard Member
Frederic LEVYFrederic LEVYBoard Member
Michelle StacyMichelle StacyBoard Member
Greg LambrechtGreg LambrechtBoard Member

Similar to Coravin

QikVin Wine PreservationQikVin Wine PreservationWest Bend, WI, USPreservation, Wineest. 2015QikVin Wine PreservationWest Bend, WI, US · est. 2015

QikVin: A hassle-free wine preservation device that expels air for natural pouring.

Angel · $126.7k2
Wine DoctorWine DoctorLas Vegas, NV, USWine Preserversest. 2008Wine DoctorLas Vegas, NV, US · est. 2008

Wine Doctor provides Intelli-Stopper wine preservers, keeping opened wine fresh and flavorful for two weeks.

Seed · $400k2
VinfolioVinfolioSan Francisco, CA, USMarketplace, Wineest. 2003VinfolioSan Francisco, CA, US · est. 2003

Vinfolio: Your trusted partner in fine wine, combining technology and service for wine enthusiasts.

Series A · $9M75
Vine VaultVine VaultAtlanta, GA, USConcierge, Wine Storageest. 2014Vine VaultAtlanta, GA, US · est. 2014

Vine Vault, established in 2015, offers comprehensive wine storage, concierge services, tastings, and exclusive wine events, managed by certified sommeliers.

Seed · $575k23

Adam Fine's Similar Executives & Operators

Lau Eng BoonLau Eng BoonBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakWillix HalimWillix HalimCEO · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakChi-hyung SongChi-hyung SongBoard Member · DunamuLee Sirg-OoLee Sirg-OoCEO · DunamuIn-hyuk ChoiIn-hyuk ChoiCEO · Naver FinancialWILL WEI CHENGWILL WEI CHENGBoard Member · DiDi

People Similar to Adam Fine

Dan BathonDan BathonBoard Member · Windspeed VenturesAdam FisherAdam FisherBoard Member · YotpoBob AdelsonBob AdelsonFounder & CEO · Osage Venture PartnersMatt SalzbergMatt SalzbergCo-Founder · AGO PartnersArup BanerjeeArup BanerjeeCo-Founder & CEO · WindfallAdam GrosserAdam GrosserBoard Member · UP Partners